Valuation: Fifty 1 Labs, Inc.

Market Cap 281K 251K 231K 210K 393K 26.65M 401K 2.75M 1.11M 14.07M 1.06M 1.03M 44.43M P/E 2009
-0.05x
P/E 2010 -0.01x
Enterprise Value 12.55M 11.21M 10.29M 9.36M 17.54M 1.19B 17.89M 123M 49.52M 627M 47.12M 46.11M 1.98B EV / Sales 2009
1.86x
EV / Sales 2010 2.41x
Free-Float
47.75%
Yield 2009 *
-
Yield 2010 -
1 day+100.00%
Current month+100.00%
1 month-33.33%
3 months-60.00%
6 months-60.00%
Current year-60.00%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0
1 year 0
Extreme 0.0001
0
3 years 0
Extreme 0.0001
0.05
5 years 0
Extreme 0.0001
0.2
10 years 0
Extreme 0.0001
0.23
Manager TitleAgeSince
Chief Executive Officer 47 -
President - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 49 30/04/2025
Chairman - 12/07/2023
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%0.00%-89.47%-99.00% 118K
-2.37%-4.19%+39.49%+63.21% 63.77B
-2.87%+0.49%+10.45%+69.18% 56.37B
+0.62%+2.11%+20.22%+102.56% 54.62B
-2.35%-4.67%+21.94%+36.94% 44.06B
-2.04%-2.09%+16.44%+99.47% 42.11B
-0.44%+3.69%+221.39%+801.56% 41B
-5.47%+24.76%+98.34%+87.34% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-1.58%+18.84%-40.44%+343.46% 24.7B
Average +8.41%+6.95%+31.32%+155.21% 39.43B
Weighted average by Cap. -1.76%+5.64%+45.31%+165.60%

Financials

2009 2010
Net sales 5.41M 4.83M 4.43M 4.03M 7.56M 512M 7.71M 52.96M 21.35M 270M 20.31M 19.88M 854M 5.11M 4.56M 4.18M 3.81M 7.14M 483M 7.28M 49.97M 20.14M 255M 19.17M 18.76M 806M
Net income -2.23M -1.99M -1.83M -1.66M -3.12M -211M -3.18M -21.84M -8.8M -112M -8.38M -8.2M -352M -1.89M -1.69M -1.55M -1.41M -2.65M -179M -2.7M -18.54M -7.47M -94.65M -7.11M -6.96M -299M
Net Debt 9.96M 8.89M 8.16M 7.42M 13.91M 943M 14.19M 97.42M 39.27M 497M 37.36M 36.57M 1.57B 12.27M 10.96M 10.05M 9.15M 17.15M 1.16B 17.49M 120M 48.41M 613M 46.06M 45.08M 1.94B
Logo Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. is a biotechnology and life sciences company. The Company focuses on peptide products, peptide discovery, AI-enabled research, and clinical development. It also focuses on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness. It owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies designed to enhance athletic performance, recovery, and overall health. It has acquired a musculoskeletal recovery product line. The product line includes five key product concepts designed to support the Company's peptide and musculoskeletal health markets. The portfolio includes natural health products focused on connective tissue recovery, inflammation support, post-surgical recovery nutrition, joint and cartilage support, and an investigational BPC-157-focused research platform.
Employees
2
Date Price Change Volume
03/11/26 USD 0.000200 +100.00% 238,888
30/10/26 USD 0.000100 -50.00% 315,000
29/10/26 USD 0.000200 0.00% 15,000
28/10/26 USD 0.000200 0.00% 804,000
27/10/26 USD 0.000200 0.00% 849,788
  1. Stock Market
  2. Stocks
  3. FITY Stock